Eli Lilly

Eli Lilly’s Earnings Spotlight Shifts From Blockbuster Sales to a Rocky Product Launch

Brett Shapiro - April 29, 2026

Eli Lilly Faces a Test of Patience as Foundayo’s Slow Start Clouds a High-Stakes Earnings Report

April 27, 2026

Eli Lilly Shares Struggle Despite Strategic Wins

angelina - April 8, 2026

Eli Lilly’s Dual-Pronged Strategy for Future Growth

angelina - April 1, 2026

Eli Lilly’s Weight-Loss Drug Shows Promise Amid Market Skepticism

angelina - March 25, 2026

Eli Lilly’s Strategic Pivot: Governance Overhaul Amidst Record Valuation Pressures

kashif hafeez - March 24, 2026

HSBC Downgrade Sparks Investor Concern Over Eli Lilly’s Growth Trajectory

kashif hafeez - March 19, 2026

Eli Lilly’s Dual-Pronged Strategy to Fortify Its Weight-Loss Market Dominance

kashif hafeez - March 12, 2026

Eli Lilly’s Strategic Horizon: Pipeline Milestones and Market Expansion

March 5, 2026

Eli Lilly Positions Oral Obesity Drug for Potential 2026 Launch

kashif hafeez - March 3, 2026

Eli Lilly’s Robust Pipeline Fuels Long-Term Growth Outlook

Brett Shapiro - February 22, 2026

Eli Lilly Bolsters Growth Trajectory with Triple Pipeline Advancements

kashif hafeez - February 20, 2026

Eli Lilly Bolsters Pipeline with Strategic Deals Following Strong Earnings

Brett Shapiro - February 11, 2026

Eli Lilly Launches Strategic Expansion with Multi-Billion Dollar Moves

February 10, 2026

Eli Lilly’s Market Leadership Strengthens on Robust Outlook

angelina - February 6, 2026

12 3 Page 1 of 3